Drug Discovery World

MAY 29, 2024

AAV purification The question of adeno-associated virus (AAV) vectors, according to Hummersone, is interesting for several reasons. Key development milestones Hummersone thinks the success of the current state of the industry can be linked to having targeted the correct sort of diseases that can benefit from CGTs.

Therapies 273

Therapies Molecular Biology DNA Immune Response 273

The Pharma Data

DECEMBER 11, 2020

Centers for Disease Control and Prevention. “This disease progresses very quickly and can get very ugly very fast. ” Hospitalization figures collected by the COVID Tracking Project show that the number of people hospitalized with the virus nationwide has doubled since the beginning of November, the Times reported.

Vaccine 52

Vaccine FDA Hospitals Doctors 52

PLOS: DNA Science

JUNE 1, 2023

The newest FDA-approved gene therapy treats the severe, skin-peeling condition dystrophic epidermolysis bullosa (DEB). The gene treatment has been a long time coming, but it differs from the handful of other approved gene therapies: it isn’t a one-and-done. This DNA Science post from 2018 traces the history of the efforts.

FDA Approval 52

FDA Approval Therapies FDA Disease 52

The Pharma Data

OCTOBER 24, 2020

That’s just not possible when the virus is surging everywhere,” Eleanor Murray, an epidemiologist at Boston University, told the Post. The winter’s cold, dry air will also help the virus stay stable longer, just as people start to spend more time indoors where ventilation may be poor. The change, issued by the U.S.

Hospitals 52

Hospitals Virus FDA Government 52

The Pharma Data

OCTOBER 23, 2020

Remdesivir gets full FDA approval to treat COVID. Remdesivir’s full approval Thursday by the FDA comes after the agency granted it emergency use authorization last spring. For patients younger than 12, the FDA will still allow the drug’s use in certain cases under its previous emergency authorization.

Hospitals 52

Hospitals Virus FDA Government 52

The Pharma Data

JANUARY 26, 2021

In November, Lilly submitted a request to the FDA for emergency use authorization (EUA) for bamlanivimab and etesevimab together as another treatment for mild to moderate COVID-19 in high-risk patients. It remains under review by the FDA. Bamlanivimab FDA Approval History. patients who recovered from COVID-19. .

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

MAY 4, 2021

Rare Disease. down 21%, driven by a negative impact from the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventative health purposes, as well as the loss of patent protection in the U.S. Panzyga is the only intravenous immunoglobulin (IVIg) with two FDA-approved maintenance dosing options for CIDP.

Vaccine 40

Vaccine Production FDA Clinical Trials 40

The Pharma Data

OCTOBER 27, 2020

National Institute of Allergy and Infectious Diseases, which sponsored the Lilly study, pulled the plug on the trial Monday — not because of any safety problem, but because there was only a slight chance that the drug would be effective, the AP said. Remdesivir gets full FDA approval to treat COVID-19. But the U.S.

Trials 52

Trials Hospitals Drugs FDA 52

The Pharma Data

NOVEMBER 23, 2020

23, 2020 – Americans were greeted with possible advances against coronavirus as Thanksgiving week began: A third vaccine candidate shows good results in shielding recipients against the virus, and an antibody therapy used by President Donald Trump against COVID-19 got emergency use approval by the U.S. MONDAY, Nov. Meanwhile, U.S.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52